Search results
Added:
1 month ago
Dr Marco Schiavone (Centro Cardiologico Monzino IRCCS, Milan, IT) and Dr Claudio Tondo (Monzino Cardiologic Centre, Milan, IT) discuss long-term durability data from an 8-year follow-up study of cryoballoon pulmonary vein isolation for atrial fibrillation.In this Journal Club session, the experts dig into real-world evidence on the extended durability of cryoballoon ablation, tackling key…
View more
Added:
1 month ago
Source:
Transcatheter Academy
One-year outcomes from the LANDMARK trial show the Myval transcatheter heart valve (THV) series is noninferior to contemporary THVs for treating symptomatic severe native aortic stenosis.¹ The results demonstrate comparable clinical efficacy and haemodynamic performance at 1 year.MethodologyLANDMARK (NCT04275726) was a prospective, randomised, open-label, noninferiority trial conducted across 31…
View more
Added:
1 year ago
Added:
5 months ago
TCT 2025 - The PREVUE-VALVE study finds an 8.2% prevalence of moderate or greater valvular heart disease amongst Americans age 65-85, increasing to 18.4% when participants with mild to moderate VHD were included.Dr David J. Cohen (Cardiovascular Research Foundation & St Francis Hospital, US) joins us to discuss findings from the PREVUE-VALVE study, examining age and sex-specific prevalence of…
View more
Added:
6 months ago
In this essential episode of Rhythm Interventions Unplugged, host Dr Devi Nair (St. Bernard's Medical Center, US) sits down with two leading experts in cardiac device management: Dr Larry Epstein and Dr Robert Schaller. Together, they explore a critical challenge facing electrophysiologists today - managing pacemaker and ICD leads in patients requiring tricuspid valve interventions.Dr Epstein and…
View more
NY Valves 2025 Late-Breaking Science Collection
Video Series
Added:
9 months ago
New York Valves 25 - Dr Tanush Gupta (UVM Medical Center, Burlington, VT, US) joins us to discuss key conversations around lifetime management for transcatheter aortic valve replacement (TAVR) patients. He discusses key data from the NOTION trial and how this has influenced his practice, as well emerging technologies such as AI simulation models and new valves.Interview Questions:How has FDA…
View more
Added:
10 months ago
EuroPCR25 - Findings from TRINITY trial show favourable outcomes with the LuX-Valve Plus TTVR system in high-risk patients with severe tricuspid regurgitation.We are joined by Prof Thomas Modine (CHU de Bordeaux, Bordeaux, FR) to discuss key findings from the TRINITY trial. This prospective, single-arm, multi-center study evaluated the LuX-Valve Plus transjugular tricuspid valve replacement…
View more
Start date:
Aug 06, 2025
Mitral and tricuspid regurgitation remain under-recognised and undertreated despite their significant impact on symptoms, quality of life, and outcomes. In this expert-led webinar, Suzanne V. Arnold, MD (Saint Luke’s Health System, Kansas City, US) offers practical guidance on recognising heart valve disease early, navigating referral pathways, and integrating patient-centred data into everyday…
View more
Added:
9 months ago
New York Valves 25 - A substudy of TRISCEND II investigating the effect of transcatheter tricuspid valve replacement (TTVR) on preference-weighted health status showed significant benefits in patients who received TTVR.We are joined by Dr Suzanne Arnold (Saint Luke's Mid America Heart Institute, US) to discuss the findings from a substudy of the TRISCEND II trial, which aimed to create an…
View more